Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRYTEC vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Hepatic via CYP3A4; also metabolized by CYP2D6 and CYP1A2 to a lesser extent.
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Approximately 70% bound to plasma proteins, primarily albumin.
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
Volume of distribution is about 0.6 to 0.8 L/kg, indicating distribution into total body water.
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral bioavailability is approximately 50% due to first-pass metabolism; intranasal bioavailability is about 70%.
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
GFR 30-50 m L/min: extend interval to every 8 hours; GFR <30 m L/min: avoid use due to pseudoephedrine accumulation.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: maximum 3 g/day paracetamol, avoid pseudoephedrine; Child-Pugh class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Children 6-12 years: 1 tablet (paracetamol 250 mg/pseudoephedrine 15 mg) orally every 4-6 hours, max 4 tablets per day; Children >12 years: adult dose.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Initiate at lowest effective dose; monitor for CNS excitation and hypertension; avoid in patients >65 years with comorbidities.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
None
None.
Use with caution in patients with severe hepatic impairment; avoid concurrent use with alcohol or CNS depressants; may cause drowsiness; not recommended during pregnancy unless benefit outweighs risk.
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Hypersensitivity to drytec or any component; severe renal impairment (Cr Cl <10 m L/min); lactation.
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid excessive caffeine intake as it may increase stimulant effects of pseudoephedrine. No specific food restrictions.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
FDA Pregnancy Category C. First trimester: Potential for fetal malformations based on animal studies; no adequate human studies. Second/third trimester: Risk of fetal tachycardia, metabolic acidosis, and possible premature labor. Avoid use in pregnancy unless benefit outweighs risk.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., tachycardia, irritability). Use caution; consider alternatives.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
Increased plasma volume and renal clearance may reduce drug levels; monitor therapeutic response. Dose adjustments may be needed; no standard guidelines. Use lowest effective dose.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
DRYTEC (pseudoephedrine/ triprolidine) combines a decongestant with a first-generation antihistamine. Avoid in hypertension, coronary artery disease, and narrow-angle glaucoma. Sedation from triprolidine may impair driving; use caution with CNS depressants. Not for children under 6 years due to risk of serious adverse effects.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Avoid alcohol and other sedatives while taking this medication.,Do not take if you have high blood pressure, heart disease, or glaucoma without consulting your doctor.,Do not drive or operate machinery until you know how this drug affects you.,Do not exceed recommended dose; prolonged use may cause rebound congestion.,Consult a doctor before use if you are pregnant or breastfeeding.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRYTEC vs AFRINOL, answered by our medical review team.
DRYTEC is a Decongestant that works by Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRYTEC and AFRINOL depend on the specific clinical indication. These are both Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRYTEC is: 1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRYTEC and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRYTEC is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for fetal malformations based on animal studies; no adequate human studies. Second/third trimester: Risk of fetal tachycardia, . AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.